Latest News and Events
Filter by
Selections
October 13, 2022
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreOctober 11, 2022
Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3
Read MoreSeptember 1, 2022
Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences
Read MoreAugust 17, 2022
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis
Read MoreJuly 8, 2022
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreJuly 5, 2022